The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Drug overdose deaths with evidence of counterfeit pill use—United States, July 2019–December 2021.
Open accessAbstract
Using data from CDC's State Unintentional Drug Overdose Reporting System, this report describes trends in overdose deaths with evidence of counterfeit pill use during July 2019-December 2021 in 29 states and the District of Columbia (DC) and characteristics of deaths with and without evidence of counterfeit pill use during 2021 in 34 states and DC. The quarterly percentage of deaths with evidence of counterfeit pill use more than doubled from 2.0% during July-September 2019 to 4.7% during October-December 2021, and more than tripled in western jurisdictions (from 4.7% to 14.7%). Illicitly manufactured fentanyls were the only drugs involved (i.e., caused death) in 41.4% of deaths with evidence of counterfeit pill use and 19.5% of deaths without evidence. Decedents with evidence of counterfeit pill use, compared with those without evidence, were younger (57.1% versus 28.1% were aged <35 years), more often Hispanic or Latino (18.7% versus 9.4%), and more frequently had a history of prescription drug misuse (27.0% versus 9.4%). Smoking was the most common noningestion drug use route among deaths with evidence of counterfeit pill use (39.5%). Overdose prevention messaging that highlights the dangers of pills obtained illicitly or without a prescription (because they might be counterfeit), encourages drug product testing by persons using drugs, and is tailored to persons most at risk (e.g., younger persons) could help prevent overdose deaths.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886 · cited 1×
“…( 6 ); providers should screen patients for opioid misuse or use disorder when opioid prescriptions are changed and link to evidence-based treatments, including medications for opioid use disorder as outlined in the 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain ( 7 ).”
BackgroundAgnoli, A. L., Xing, G., Tancredi, D. J., Magnan, E., Jerant, A. F., & Fenton, J. J. (2021) · JAMA · doi:10.1001/jama.2021.11013 · Cited by 284
Transition from injecting opioids to smoking fentanyl in San Francisco, California
Kral, A. H., Lambdin, B. H., Browne, E. N., Wenger, L. D., Bluthenthal, R. N., Zibbell, J. E., & Davidson, P. J. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109003 · Cited by 150
Palamar, J. J., Ciccarone, D., Rutherford, C., Keyes, K. M., Carr, T. H., & Cottler, L. B. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109398 · Cited by 147
Counterfeit Medications and Fentanyl
Green, T. C., & Gilbert, M. K. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.4310 · Cited by 125
Russell, C., Law, J., Bonn, M., Rehm, J. T., & Ali, F. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103933 · Cited by 100
Winer, J. M., Yule, A. M., Hadland, S. E., & Bagley, S. M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2104922 · Cited by 70
Daniulaityte, R., Sweeney, K. R., Ki, S., Doebbeling, B. N., & Mendoza, N. S. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00634-4 · Cited by 47
Barbero (2014) · doi:10.1016/j · Cited by 1
Flagged first, then by citations
Research works printed but not linked: 1
- Howland M. Pharmacokinetic and toxicokinetic principles [Chapter 9]. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank’s toxicologic emergencies, 11th ed. New York, NY: McGraw Hill; 2019.
Cited by
Sorted by citations
Routes of Drug Use Among Drug Overdose Deaths — United States, 2020–2022
Tanz, L. J., Gladden, R. M., Dinwiddie, A. T., Miller, K. D., Broz, D., Spector, E. A., & O’Donnell, J. K. (2024) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7306a2 · Cited by 127
Self-citationTanz, L. J., Stewart, A., Gladden, R. M., Ko, J. Y., Owens, L. E., & O’Donnell, J. K. (2024) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7348a2 · Cited by 81
Self-citationCommunity-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths
The HEALing Communities Study Consortium (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401177 · Cited by 76
Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon
Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., & del Pozo, B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.31612 · Cited by 52
Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years
Han, B., Jones, C. M., Volkow, N. D., Rikard, S. M., Dowell, D., Einstein, E. B., Guy, G. P., Tomoyasu, N., Ko, J. Y., Baldwin, G. T., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0054 · Cited by 49
National and regional trends in fentanyl seizures in the United States, 2017–2023
Palamar, J. J., Fitzgerald, N. D., Carr, T. H., Cottler, L. B., & Ciccarone, D. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104417 · Cited by 42
Decrease in injection and rise in smoking and snorting of heroin and synthetic opioids, 2000–2021
Karandinos, G., Unick, J., Ondocsin, J., Holm, N., Mars, S. G., Montero, F., Rosenblum, D., & Ciccarone, D. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111419 · Cited by 42
The public health risks of counterfeit pills
Friedman, J., & Ciccarone, D. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00273-1 · Cited by 32
Public health surveillance of new psychoactive substances: recent developments
Fitzgerald, N. D., Cottler, L. B., & Palamar, J. J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000938 · Cited by 33
Connolly, S., Govoni, T. D., Jiang, X.-Y., Terranella, A., Guy, G., Green, J. L., & Mikosz, C. A. (2024) · MMWR. Morbidity and mortality weekly report · doi:10.15585/mmwr.mm7305a1 · Cited by 22
Naloxone Dispensing to Youth Ages 10–19: 2017–2022
Terranella, A., Guy, G. P., & Mikosz, C. A. (2024) · PEDIATRICS · doi:10.1542/peds.2023-065137 · Cited by 19
Changes in Synthetic Opioid–Involved Youth Overdose Deaths in the United States: 2018–2022
Miller, M. J., Wheeler-Martin, K., Bunting, A. M., Cerdá, M., & Krawczyk, N. (2025) · PEDIATRICS · doi:10.1542/peds.2024-069488 · Cited by 17
The Fourth Wave of the Opioid Epidemic: Increasing Combination of Fentanyl With Stimulants
Diekhans, K., Yu, J., Pearring, S., Almeida, R., & Rodda, L. N. (2025) · American Journal of Public Health · doi:10.2105/ajph.2024.307948 · Cited by 19
Laffont, C. M., Purohit, P. G., Delcamp, N., Gonzalez-Garcia, I., & Skolnick, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1399803 · Cited by 16
Nonfatal pediatric fentanyl exposures reported to US poison centers, 2015–2023
Palamar, J. J., Cottler, L. B., & Black, J. C. (2025) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2025.2457481 · Cited by 11
Kononova, A. G., Huddleston, P., Moldagaliyeva, M., Lee, H., & Alhabash, S. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1394660 · Cited by 10
Aronson, I. D., Ardouin-Guerrier, M.-A., Baus, J. E., & Bennett, A. S. (2024) · JMIR Formative Research · doi:10.2196/56755 · Cited by 9
Chandra, J., Charpignon, M., Bhaskar, A., Therriault, A., Chen, Y., Mooney, A. C., Dahleh, M. A., Kiang, M. V., & Dominici, F. (2024) · American Journal of Public Health · doi:10.2105/ajph.2024.307618 · Cited by 8
Use of Illegally Manufactured Fentanyl in the United States: Current Trends
Fitzgerald, N. D., Palamar, J. J., & Cottler, L. B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00625-y · Cited by 9
Ciccarone, D. (2025) · Journal of Medical Toxicology · doi:10.1007/s13181-025-01104-6 · Cited by 10
Suspected North Carolina counterfeit pill-involved deaths, 2020–2022
Friederich, L., Cox, M. E., Hyson, B. E., & Bishop-Freeman, S. C. (2024) · Journal of Analytical Toxicology · doi:10.1093/jat/bkae027 · Cited by 8
Glidden, E. V., Gladden, R. M., Dion, C., Spyres, M. B., Seth, P., Aldy, K., & Mustaquim, D. (2024) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7329a2 · Cited by 8
Hall, E. W., Sullivan, P. S., & Bradley, H. M. (2024) · JMIR Public Health and Surveillance · doi:10.2196/49527 · Cited by 7
Pal, E., Merchant, L., Koffi, A. K., Mehta, R., Rusatira, J. C., Kubiak, L., Michtalik, H. J., Caubel, P., & Ahmed, S. (2025) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2025.2550369 · Cited by 9
Biswakarma, A., & Miao, W. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06407 · Cited by 6
Ragan, K. R., Schieber, L. Z., Terranella, A., & Mikosz, C. A. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.11579 · Cited by 6
Treating Benzodiazepine Withdrawal in a Bridge Clinic
Laks, J., Kim, T. W., Christine, P. J., Evans, J. C., Farrell, N. M., Kehoe, J., Younkin, M., & Taylor, J. L. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001334 · Cited by 5
Preventing Substance Use and Overdose Among Young Adults: The Role of Social Determinants of Health
Jones, C. M. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240022 · Cited by 4
The Police Opioid Seizure Temporal Risk (POSTeR) model of increased exposure to fatal overdose
del Pozo, B., Green, T. C., Godvin, M., & Ray, B. R. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104789 · Cited by 4
Bly, C., Guy, G. P., Mikosz, C. A., & Terranella, A. (2025) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2025.08.026 · Cited by 4
Smith, R., McMahan, V., McCann, N. C., Kosakowski, S., Brennan, S., Marti, X. L., Walley, A. Y., & Coffin, P. O. (2025) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2025.100351 · Cited by 3
Mini-review: Harm reduction strategies among people who intentionally use fentanyl
Paredes, J., Sandhu, A., Huo, S., & Timberlake, D. S. (2025) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2025.100615 · Cited by 4
Palamar, J. J., Fitzgerald, N. D., & Carr, T. H. (2025) · Drug and Alcohol Review · doi:10.1111/dar.14022 · Cited by 2
A Scoping Review of Youth Overdose Prevention Interventions
Renehan, C. M., Wiggins, M., Puppala, R., Chatterjee, A., Obando, A. M., Coleman, K. R., Raj, A., Schmill, D. M., Flynn, D., & Bagley, S. M. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001501 · Cited by 2
Education Improves Perceived Control but Not Risk Identification in Adolescents Regarding Fentanyl
Bakos‐Block, C., Vega, F. R., Cárdenas-Turanzas, M., Gopal, B., & Champagne‐Langabeer, T. (2025) · Children · doi:10.3390/children12060794 · Cited by 2
Effects of Peer-to-Peer Opioid Overdose and Naloxone Training in Adolescents
Puzantian, T., Atkinson, O., SOLOMON, J. M., Liu, J., & Parga, E. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2522150 · Cited by 2
Fitzgerald, N. D., Palamar, J. J., & Cottler, L. B. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70119 · Cited by 2
Jayawardene, W. P., Magnuson, R., Kumbalatara, C., Kase, M., Park, A., Goodson, A., Barrows, S., Bolinski, R. S., & Willett, J. (2025) · Healthcare · doi:10.3390/healthcare13121449 · Cited by 2
Liu, Y.-L., & Wei, L. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2421862 · Cited by 1
Yule, A. M., Bohnert, A. M., Ridenour, T. A., Montgomery, B. W., Wilens, T. E., Walton, M. A., Bonar, E. E., Saldana, L., Fiellin, L. E., Knight, D. K., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112921 · Cited by 1
Colston, D. C., Go, V. F.-L., Barrington, C., Sibley, A. L., Piscalko, H. M., Limarzi-Klyn, L., & Miller, W. C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0338689 · Cited by 1
Zhan, Z., Tian, S., Qiu, J., Zuo, S., & Wang, Y. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119521 · Cited by 1
Drug Overdose Deaths in Adolescents and Young Adults in Arizona, 2018–2022
Cano, M. N., & Timmons, P. (2025) · Journal of Child & Adolescent Substance Use · doi:10.1080/29973368.2025.2490653 · Cited by 1
Daniulaityte, R., Sweeney, K. R., Timmons, P., Hooten, M., Williams, E., Coles, H., Russell, D. M., & LoVecchio, F. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104808 · Cited by 1
Drug decriminalization, the introduction of fentanyl to drug markets, and fatal overdose in OregonPreprint
Zoorob, M. J., Park, J. N., Kral, A. H., Lambdin, B. H., & del Pozo, B. (2024) · medRxiv · doi:10.1101/2024.04.08.24305508 · Cited by 1
Estimating the Prevalence of Using Suspected Counterfeit Medications in the General Population
Jewell, J. S., Bemis, E. A., & Black, J. C. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001326
Neurological Aspects of Substance Use Disorder: An Introduction
McArthur, J. C., & Stitt, D. W. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1787551
Changes Over Time in Naloxone Dosing and Route in Adolescent Opioid Toxicity
Sidlak, A. M., Goncalves, M., Ahmed, R., & Dhaliwal, M. (2025) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.04.006
Vekaria, V., Xi, W., Patra, B. G., Murphy, S. M., Avery, J., Olfson, M., & Pathak, J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209792
Han, H.-C., Huang, D., & Chen, C. (2025) · Computer Modeling in Engineering & Sciences · doi:10.32604/cmes.2025.070944 · Cited by 1
Colston, D. C., Sibley, A. L., Joniak-Grant, E., Mortensen, H., Swilley-Martinez, M. E., Pence, B. W., Go, V. F.-L., & Ranapurwala, S. I. (2026) · Harm Reduction Journal · doi:10.1186/s12954-026-01440-y
Identification of distinct stimulant use trajectories and patterns of overdose
Shaw, L. C., Li, Y., Noguchi, J. E., Park, C. J., Biello, K. B., Hadland, S. E., Sherman, S. G., Macmadu, A., & Marshall, B. D. L. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100709
Survival Following a Fentanyl-Related Mass Casualty Event: A Case Report
Au, K., Fan, R., Leo, A., & Chu, G. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0018
Dinis‐Oliveira, R. J., & Barbosa, D. J. (2026) · Psychoactives · doi:10.3390/psychoactives5030023
Emotional Neglect in Childhood and Benzodiazepine Misuse in Rhode Island Young Adults
Bradford, C., & Rosenthal, S. R. (2026) · Addiction & Prevention · doi:10.3390/addictprev1010006
Yu, K., Medeiros, E. A., Dillon, D. G., Chenoweth, J., & Owen, C. (2026) · Legal Medicine · doi:10.1016/j.legalmed.2026.102993
Voetsch, K., Wolff, J., & Baldwin, G. T. (2026) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000002464
Self-citationOxycodone at the Crossroads of Pain Management, Misuse, and Toxicological Investigation
Ślebioda, D., Ślęczka, M. A., Skowron, I., Stanclik, M., Mikłuszka, M., & Chłopaś‐Konowałek, A. (2026) · Metabolites · doi:10.3390/metabo16100719
Metadata
- Authors
- O’Donnell, J., Tanz, L. J., Miller, K. D., Dinwiddie, A. T., Wolff, J., Mital, S., Obiekwe, R., & Mattson, C. L.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2023-09-01
- Volume
- 72
- Issue
- 35
- Pages
- 949-956
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W4386307469
- Cited by
- 58
- References
- 8
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 23
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- MMWR Morbidity and Mortality Weekly Report (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- National Center for Injury Prevention and Control
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- drug overdose deaths, illicitly manufactured fentanyl, fentanyl analogs, prescription drug misuse
- MeSH terms
- Centers for Disease Control and Prevention, U.S., Commerce, District of Columbia, Humans, United States, Drug Overdose, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review